Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-17T10:20:55.184Z Has data issue: false hasContentIssue false
  • English
  • Français

Ziprasidone-Associated Mania in a Case of Obssessive-Compulsive Disorder

Published online by Cambridge University Press:  07 November 2014

Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

A PubMed search revealed 14 cases of ziprasidone associated mania, which carried primary diagnoses of mood disorders, generalized anxiety disorders (GAD), panic disorder, and psychotic disorders. To our knowledge, we report the first case of mania associated with ziprasidone augmentation of a selective serotonin reuptake inhibitor in a 60-year-old man (at time of ziprasidone-induced mania) with obssessive-compulsive disorder (OCD).

In May 2002, after partial response to citalopram 80 mg and low-dose clonazepam 1.5 mg/day in three divided doses, ziprasidone was initiated as an augmenting agent at a dose of 20 mg/day and increased to 20 mg BID. Within 7 days of starting ziprasidone family members noted a decreased need for sleep, impulsivity, grandiosity, and increased energy. He was brought to the emergency room after 17 days with florid manic symptoms. Physical and neurological exams were unremarkable. Routine laboratory work, including a drug screen, was non-contributory. His non-psychiatric medications included fexofenadine, hydroxyzine, and sodium nitroprusside. He was hospitalized and ziprasidone was stopped with reduction in the dose of citalopram to 20 mg. Manic symptoms promptly resolved within 3 days.

Type
Communique
Information
CNS Spectrums , Volume 12 , Issue 8 , August 2007 , pp. 578 - 579
Copyright
Copyright © Cambridge University Press 2007

References

REFERENCES

1.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: America Psychiatric Association; 1994.Google Scholar
2.Privitera, MR, Maharaj, K. Mania from dose related ziprasidone augmentation of an SSRI. J Clin Psychiatry. 2003;64:1393–1394.CrossRefGoogle ScholarPubMed
3.Patel, NC, Keck, PE Jr.Ziprasidone: efficacy and safety in patients with bipolar disorder. Expert Rev Neurother. 2006;6:1129–1138.CrossRefGoogle ScholarPubMed
4.Crane, DL. Ziprasidone as an augmenting agent in treatment of anxiety-spectrum disorders. CNS Spectr. 2005;10:176–179.CrossRefGoogle ScholarPubMed
5.Duggal, H, Sigh, I. Ziprasidone and hypomania. CNS Spectr. 2005;10:606.Google ScholarPubMed